Parliamentary QA
CONSIDERATIONS IN INCLUSION OR REMOVAL OF TREATMENTS IN CANCER DRUG LIST
9 January 2024
This article has been migrated from an earlier version of the site and may display formatting inconsistencies.
NOTICE PAPER NO. 2456
NOTICE OF QUESTION FOR WRITTEN ANSWER
FOR THE SITTING OF PARLIAMENT ON 9 JANUARY 2024
Name and Constituency of Member of Parliament
Assoc Prof Jamus Jerome Lim
MP for Sengkang GRC
Question No. 5305
To ask the Minister for Health (a) what are the considerations that the Ministry takes into account when deciding the treatments to be included in the Cancer Drug List; and (b) what factors typically lead to the inclusion or removal of a particular drug from the List.
Answer
1 The key factors that the Agency for Care Effectiveness considers are that treatments should be both clinically-effective and cost-effective, in order to be included in the Cancer Drug List (CDL).
2 For treatments that are already assessed and on the CDL, they will remain on the list unless there are specific reasons to remove them, such as if the company defaults on contractual agreements with MOH or upon company request or safety recalls.